TREATMENT REGIMEN

EASL 2016 Recommendations for treatment of HCV monoinfection or co-infection with HIV / HCV patients without cirrhosis , including previously treated with therapy and patients who have suffered virologic failure during therapy with pegylated interferon and ribavirin.

Genotype SOF + VEL SOF + LED SOF + DAC
Genotype 1a 12 weeks. 8-12 weeks. 12 weeks.
Genotype 1b 12 weeks. 8-12 weeks. 12 weeks.
Genotype 2 12 weeks. 12 weeks.
Genotype 3 12 weeks. 12 weeks.
Genotype 4 12 weeks. 12 weeks. 12 weeks.

Recommendations EASL 2016 to therapy monoinfection HCV or co-infection with HIV / HCV patients with compensated cirrhosis (class A on Child-Pugh), including previously treated with therapy and patients who have suffered virologic failure during therapy with pegylated interferon and ribavirin

Genotype SOF + VEL SOF + LED SOF + DAC
Genotype 1a 12 weeks. + RBV or 24 weeks. without RBV 12 weeks. + RBV or 24 weeks. without RBV *** 12 weeks. + RBV or 24 weeks. without RBV
Genotype 1b 12 weeks. + RBV or 24 weeks. without RBV 12 weeks. + RBV or 24 weeks. without RBV *** 12 weeks. + RBV or 24 weeks. without RBV
Genotype 2 12 weeks. + RBV or 24 weeks. without RBV 12 weeks. + RBV or 24 weeks. without RBV
Genotype 3 12 weeks. + RBV or 24 weeks. without RBV 24 weeks. + RBV
Genotype 4 12 weeks. + RBV or 24 weeks. without RBV 12 weeks. + RBV or 24 weeks. without RBV *** 12 weeks. + RBV or 24 weeks. without RBV

*** – In the presence of predictors of poor response – 24 weeks in combination with ribavirin;
RBV – ribavirin; VEL – velpatasvir;